## Caterina Lanna

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4064423/publications.pdf

Version: 2024-02-01

623188 642321 41 675 14 23 h-index citations g-index papers 42 42 42 786 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Apremilast as a target therapy for nail psoriasis: a real-life observational study proving its efficacy in restoring the nail unit. Journal of Dermatological Treatment, 2022, 33, 1097-1101.	1.1	10
2	Psoriasis in difficult to treat areas: treatment role in improving health-related quality of life and perception of the disease stigma. Journal of Dermatological Treatment, 2022, 33, 531-534.	1.1	12
3	Skin advanced glycation end products as a diagnostic and monitoring tool among psoriatic patients: how the therapy helps reduce cardiovascular disease risk. International Journal of Dermatology, 2022, 61, 577-581.	0.5	4
4	The Role of Glutathione-S Transferase in Psoriasis and Associated Comorbidities and the Effect of Dimethyl Fumarate in This Pathway. Frontiers in Medicine, 2022, 9, 760852.	1,2	14
5	Coesisting inflammatory skin diseases: Tildrakizumab to control psoriasis and Omalizumab for urticaria. Dermatologic Therapy, 2022, , e15359.	0.8	5
6	Early clinical response to 5-fluorouracil 0.5% and salicylic acid 10% topical solution in the treatment of actinic keratoses of the head: an observational study. Journal of Dermatological Treatment, 2022, 33, 2664-2669.	1.1	4
7	Interaction of Pelargonium sidoides Compounds with Lactoferrin and SARS-CoV-2: Insights from Molecular Simulations. International Journal of Environmental Research and Public Health, 2022, 19, 5254.	1.2	5
8	Clinical efficacy and reflectance confocal microscopy monitoring in moderateâ€severe skin aging treated with a polyvinyl gel containing retinoic and glycolic acid: An assessorâ€blinded 1â€month study proofâ€ofâ€concept trial. Journal of Cosmetic Dermatology, 2021, 20, 310-315.	0.8	8
9	Trifarotene: A Current Review and Perspectives in Dermatology. Biomedicines, 2021, 9, 237.	1.4	36
10	Antifungal Effect of All- <i>trans</i> Retinoic Acid against Aspergillus fumigatus <i>In Vitro</i> and in a Pulmonary Aspergillosis <i>In Vivo</i> Model. Antimicrobial Agents and Chemotherapy, 2021, 65, .	1.4	16
11	Lactoferrin Against SARS-CoV-2: In Vitro and In Silico Evidences. Frontiers in Pharmacology, 2021, 12, 666600.	1.6	61
12	Experimental Pharmacological Management of Psoriasis. Journal of Experimental Pharmacology, 2021, Volume 13, 725-737.	1.5	15
13	Psychological symptoms in dermatologic patients during the COVID-19 lockdown period: a double center experience. Italian Journal of Dermatology and Venereology, 2021, 156, 392-393.	0.1	1
14	Effectiveness of a cosmetic device containing a combination of alpha―and betaâ€hydroxy acids, urea, and thuja for the treatment of seborrheic keratoses. Journal of Cosmetic Dermatology, 2021, , .	0.8	3
15	Pharmacogenomics: An Update on Biologics and Small-Molecule Drugs in the Treatment of Psoriasis. Genes, 2021, 12, 1398.	1.0	25
16	Lactoferrin as Antiviral Treatment in COVID-19 Management: Preliminary Evidence. International Journal of Environmental Research and Public Health, 2021, 18, 10985.	1.2	47
17	Patidegib in Dermatology: A Current Review. International Journal of Molecular Sciences, 2021, 22, 10725.	1.8	12
18	Unexpected intranasal basal cell carcinoma. Italian Journal of Dermatology and Venereology, 2021, 156, 104-105.	0.1	1

#	Article	lF	CITATIONS
19	Skin immunity and its dysregulation in atopic dermatitis, hidradenitis suppurativa and vitiligo. Cell Cycle, 2020, 19, 257-267.	1.3	22
20	Birt–Hogg–Dubé syndrome, from nonâ€invasive dermatologic assessment to gene testing, molecular and ultrastructural histologic analysis. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e206-e209.	1.3	1
21	Lactoferrin as Protective Natural Barrier of Respiratory and Intestinal Mucosa against Coronavirus Infection and Inflammation. International Journal of Molecular Sciences, 2020, 21, 4903.	1.8	83
22	Latest Evidence Regarding the Effects of Photosensitive Drugs on the Skin: Pathogenetic Mechanisms and Clinical Manifestations. Pharmaceutics, 2020, 12, 1104.	2.0	17
23	Overview of the molecular determinants contributing to the expression of Psoriasis and Psoriatic Arthritis phenotypes. Journal of Cellular and Molecular Medicine, 2020, 24, 13554-13563.	1.6	41
24	Improving of psychological status and inflammatory biomarkers during omalizumab for chronic spontaneous urticaria. Future Science OA, 2020, 6, FSO618.	0.9	4
25	High-Risk Recurrence Basal Cell Carcinoma: Focus on Hedgehog Pathway Inhibitors and Review of the Literature. Chemotherapy, 2020, 65, 2-10.	0.8	17
26	A Case of Pincer Nail Successfully Treated with Tazarotene 0.1% Gel. Case Reports in Dermatology, 2020, 12, 114-118.	0.3	3
27	Melanocytic lesion in children and adolescents: an Italian observational study. Scientific Reports, 2020, 10, 8594.	1.6	5
28	Predictive role of vitamin A serum concentration in psoriatic patients treated with IL-17 inhibitors to prevent skin and systemic fungal infections. Journal of Pharmacological Sciences, 2020, 144, 52-56.	1.1	29
29	Real life experience of apremilast in psoriasis and arthritis psoriatic patients: Preliminary results on metabolic biomarkers. Journal of Dermatology, 2020, 47, 578-582.	0.6	34
30	Efficacy and safety of adalimumab in difficultâ€ŧoâ€ŧreat psoriasis. Dermatologic Therapy, 2020, 33, e13374.	0.8	14
31	Dimethylfumarate efficacy and safety in palmoplantar psoriasis patient affected by <scp>hepatitis b</scp> and depression: A case report. Dermatologic Therapy, 2020, 33, e13659.	0.8	3
32	Skin immunity and its dysregulation in psoriasis. Cell Cycle, 2019, 18, 2581-2589.	1.3	21
33	Investigational drugs currently in phase II clinical trials for actinic keratosis. Expert Opinion on Investigational Drugs, 2019, 28, 629-642.	1.9	8
34	One drug and two diseases: A case of multidrugâ€resistant hidradenitis suppurativa and psoriasis treated with apremilast. Dermatologic Therapy, 2019, 32, e13089.	0.8	7
35	Omalizumab for chronic spontaneous urticaria in "complex―patients: data from real-life clinical practice. Drug Design, Development and Therapy, 2019, Volume 13, 3181-3186.	2.0	10
36	Nails as immuneâ€privileged sites: A case of disabling Acrodermatitis continua of Hallopeau successfully treated with Apremilast. Dermatologic Therapy, 2019, 32, e12946.	0.8	7

#	Article	IF	CITATION
37	Basal cell carcinomas treated with 0.5% 5â€fluorouracil and 10% salicylic acid topical solution. Dermatologic Therapy, 2019, 32, e12908.	0.8	3
38	<p>The Effectiveness of a New Topical Formulation Containing GSH-C4 and Hyaluronic Acid in Seborrheic Dermatitis: Preliminary Results of an Exploratory Pilot Study</p> . Clinical, Cosmetic and Investigational Dermatology, 2019, Volume 12, 881-885.	0.8	4
39	<p>Small Molecules, Big Promises: Improvement of Psoriasis Severity and Glucidic Markers with Apremilast: A Case Report</p> . Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2019, Volume 12, 2685-2688.	1.1	8
40	Is the prevalence of hidradenitis suppurativa being overestimated in Europe? Or is the disease underdiagnosed? <i>Evidence from a nationwide study across Portuguese public hospitals </i> International Journal of Dermatology, 2017, 56, 1491-1492.	0.5	7
41	Hospitalisations with Hidradenitis Suppurativa: An Increasing Problem That Deserves Closer Attention. Dermatology, 2016, 232, 613-618.	0.9	34